Transverse Myelitis Treatment Market

Transverse myelitis is a rare inflammatory disease. It is caused by inflammation of the spinal cord. Generally, transverse myelitis damages the insulating material covering nerve cell fibers (myelin).

Signs and symptoms of transverse myelitis include pain, weakness in arms or legs, abnormal sensations, and bladder & bowel problems. Patients suffering from transverse myelitis report coldness or burning, numbness, and tingling. The exact cause of transverse myelitis is unknown. According to PubMed studies, transverse myelitis can be caused by multiple sclerosis, autoimmune disorders, Devic's disease, and infections of the gastrointestinal tract. Major complications of transverse myelitis are sexual dysfunction, stiffness, tightness or painful spasms, depression, or anxiety.

Doctors or professionals can diagnose transverse myelitis based on medical history and tests. Common diagnostic tests for transverse myelitis are lumbar puncture (spinal tap), blood tests, and magnetic resonance imaging (MRI).

Rise in prevalence of transverse myelitis across the world is anticipated to drive the global transverse myelitis treatment market during the forecast period. A rise in government prioritization of drugs for rare disorders is also expected to propel the global market in the near future. Moreover, shortage of health care experts in Latin America and Middle East & Africa hampers the growth of the transverse myelitis treatment market in the regions. Nevertheless, increase in government funding for diagnostic procedures is likely to augment the transverse myelitis treatment market. Organizations supporting the treatment of this disease globally are the Genetic and Rare Diseases (GARD) Information Center, the NIH/National Institute of Neurological Disorders and Stroke, the Academy of Spinal Cord Injury Professionals, Inc., and the Transverse Myelitis Association.

The global transverse myelitis treatment market can be segmented based on treatment, end-user, and region. In terms of treatment, the market can be bifurcated into drugs and therapies. The drugs segment can be classified into intravenous steroids, antiviral medication, pain medication, and others. The therapies segment can be categorized into physical therapy, occupational therapy, and psychotherapy. Methylprednisolone and dexamethasone are the common steroids used for the treatment of transverse myelitis. Occupational therapy and physical therapy have been effective in some patients. Chronic pain is a common complication of transverse myelitis. Doctors recommend common pain relievers such as acetaminophen, naproxen and ibuprofen.

In terms of end-user, the global transverse myelitis treatment market can be divided into hospitals, special clinics, and others. The hospitals segment held significant share of the market in 2017.

Based on region, the global transverse myelitis treatment market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America accounted for major share of the global market in 2017, followed by Europe and Asia Pacific. The U.S. held significant share of the market in North America in terms of revenue. The transverse myelitis treatment market in Asia Pacific is growing rapidly due to increase in the number of patients suffering from the disorder. Better health care infrastructure, economic growth, rise in the number of insurance payers, expanding & developing private health care sector, and increase in awareness among people about transverse myelitis treatment are expected to propel the market in the region in the next few years. The transverse myelitis treatment market in Latin America and Middle East & Africa is projected to expand at a moderate growth rate from 2018 to 2026.

Key players operating in the global transverse myelitis treatment market include Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc., WOCKHARDT, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Baxter, Amerigen Pharmaceuticals Limited, and Novartis AG.